Analysis of drug resistance to six kinds of nucleoside analogues in 1507 patients with viral hepatitis B

doi:10.3877/cma.j.issn.2095-5820.2018.01.011

Abstract

Abstract:

Objective

To analyze the drug resistance of hepatitis B virus (HBV) in patients under antiviral therapy with nucleoside analogues.

Methods

The patients were from the overall country of China and the specimens were tested in Guangzhou Kingmed Center for Clinical Laboratory during Jan 1, 2016 and Mar 25, 2016. The nucleoside analogues resistance genes were detected in 1507 patients with hepatitis B, and the drug resistance of six common nucleoside analogues were collected and classified.

Results

The drug-resistance of lamivudine (LAM), telbivudine (LDT) and emtrichomes (FTC) were serious, and the drug resistance rates were 35.24 %. The drug-resistance of adefovir (ADV) and entecavir (ETV) were also high, which were 14.93 % (225/1507) and 7.70 %(116/1507), respectively. No strain resistant to tenofovir (TDF) were found in the 1507 cases.

Conclusions

Low drug resistance barrier drugs including lamivudine, telbivudine and emtrichomes have severe resistance. Nucleoside analogues resistance gene monitoring is effective in the formulation of drug use protocols. It has an important clinical significance to improve the prognosis of patients and track investigation of drug resistance situation to reduce or delay the production of drug resistant strains.

Key words: Hepatitis B virus, Drug resistance, Chronic hepatitis B, Rational drug use

Weiwei Wu. Analysis of drug resistance to six kinds of nucleoside analogues in 1507 patients with viral hepatitis B[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2018, 06(01): 43-46.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2018.01.011

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2018/V06/I01/43

Figures/Tables 2

References 10

1	李金明. 实时荧光PCR技术[M]. 北京：人民军医出版社, 2015:190-191.
2	曹灵芝，樊正勤，赵耕. 慢性乙型肝炎患者基因耐药变异特征分析[J]. 中国实用医药, 2016,11(14):53-54.
3	Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleostide therapy: a systematic review[J]. Hepatol, 2010,53(2):348-356.
4	王健，韩忠燕，周娜，等. CXCL8及其受体CXCR1、CXCR2在慢性乙肝患者外周血PMNs中的表达[J]. 中国免疫学杂志, 2015,17(3):375-379.
5	郑波. 拉米夫定联合阿德福韦酯治疗HBeAg阳性失代偿期乙型肝炎肝硬化患者的临床疗效[J]. 吉林医学, 2016,37(10):2412-2413.
6	陈韧刚，魏三舟，胡汉国. LAM和ECV联合治疗慢性乙肝患者对乙肝病毒耐药基因多位点变异特点分析[J]. 临床医学研究与实践, 2016,1(16):87-88.
7	刘仁志，夏璀. 核苷类似物联合治疗拉米夫定不同耐药位点慢性乙型肝炎患者的疗效观察[J]. 临床医学工程, 2016,23(8):1036-1038.
8	张凯，刘妍，徐东平，等. 慢性HBV感染的抗病毒治疗方法优化现状及展望[J]. 传染病信息, 2016,29(2):65-67.
9	张树永，陈琛，马庆伟，等. 乙型肝炎抗病毒治疗中的耐药基因突变检测技术[J]. 传染病信息, 2016,29(5):311-314.
10	姜清明. 乙型肝炎病毒耐药突变基因的检测与分析[J]. 中国医学工程, 2017,25(2): 84-86.

药物名称	耐药敏感性(例)				敏感度(%)	耐药率(%)
药物名称	S	U	I	R	敏感度(%)	耐药率(%)
拉米夫定	772	53	151	531	51.22	35.24
替比夫定	973	0	3	531	64.57	35.24
恩曲他滨	973	0	3	531	64.57	35.24
阿德福韦	1167	115	0	225	77.44	17.93
替诺福韦	1415	0	92	0	93.90	0.00
恩替卡韦	972	0	419	116	64.50	7.70

药物名称	耐药敏感性(例)				敏感度(%)	耐药率(%)
药物名称	S	U	I	R	敏感度(%)	耐药率(%)
拉米夫定	772	53	151	531	51.22	35.24
替比夫定	973	0	3	531	64.57	35.24
恩曲他滨	973	0	3	531	64.57	35.24
阿德福韦	1167	115	0	225	77.44	17.93
替诺福韦	1415	0	92	0	93.90	0.00
恩替卡韦	972	0	419	116	64.50	7.70

药物名称	B	C	D	C/D重组型
拉米夫定	142	384	1	4
替比夫定	142	384	1	4
恩曲他滨	142	384	1	4
阿德福韦	46	176	1	2
替诺福韦	0	0	0	0
恩替卡韦	27	87	0	2

药物名称	B	C	D	C/D重组型
拉米夫定	142	384	1	4
替比夫定	142	384	1	4
恩曲他滨	142	384	1	4
阿德福韦	46	176	1	2
替诺福韦	0	0	0	0
恩替卡韦	27	87	0	2

[1]	Yu Zhang, Song Yang. Interpretation of 2024 World Health Organization guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(03): 129-134.
[2]	Lin Zhu, Tao Chen, Shen Zhang, Dong Xu. Changes of the structure and resistance of pathogenic bacteria in the department of infectious diseases of a tertiary hospital in central China in the past ten years [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(02): 75-82.
[3]	Guanmei Chen, Xuan Zuo, Baolin Liao. Recent progress on novel immunotherapy in the treatment of chronic hepatitis B [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(01): 7-10.
[4]	Jiayi Xing, Jiasheng Gong, Jiajia Zhu, Qun Lu. Analysis of pathogenic drug resistance and inflammatory factor changes in secondary pulmonary infection in chemotherapy patients with lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(05): 714-718.
[5]	Hui Yang, Lijuan Guo, Xiaodan Feng, Jing LI, Chengmo Huang, Xingrui Cai, Yingjiao Qin, Yuanli Wang. Expression characteristics and prediction analysis of platinum-resistant mi RNA in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(05): 719-724.
[6]	Jian Zhang, Conghua Lu, Jianghua Li, Caiyu Lin, Di Wu, Zhiguo Wang, Naifu Nie, Yong He, Li Li. Transcriptomics-based exploration of the mechanism of acquired resistance to Osimertinib [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(02): 195-200.
[7]	Lei Xing, Jingqi Shi, Rongyan Li, Jing Liu, Jianwei Liu, Ling Ye, Minghua Zhang, Jiao Fan. Mechanisms of drug resistance to the neddylation inhibitor MLN4924 in NCI-H460 cells based on transcriptome sequencing analysis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(01): 1-10.
[8]	Minsi Liu, Rong Li, Mei Li. Diagnostic value of GGT-Plt ratio-based model for HBV-related hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 831-835.
[9]	Xiangqian Wang, Qingfeng Li, Lei Chen, Wendan Qiu, Zhicheng Yao, Yi Li, Ronghuan Wu. Inhibitory effect of curcumin on sorafenib resistance in hepatocellular carcinoma and its regulatory mechanism [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 729-735.
[10]	Jia Dong, Kun Wang, Li Zhang. Prognostic nutritional index combined with immunoglobulin，fasting blood glucose level and serum alpha-fetoprotein in predicting poor prognosis in patients with HBV associated chronic acute liver failure after treatment [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 555-559.
[11]	Jing Hu, Xiujin Yang, Zhiyun Hou. Changes of peripheral blood ISGs and their relationship with curative effect of interferon therapy in patients with HBV infection [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 343-347.
[12]	Hao Jiang, Hongsheng Yu, Bilan Yang, Smayi Abdukyamu, Bin Wu, Yidong Yang. Nomogram model-based clinical prediction of advanced hepatic fibrosis in patients with chronic hepatitis B complicated by hepatic steatosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(02): 114-120.
[13]	Ma Li, Ling Yan, Yun Xi, Shangxia Li, Donglin Zhu. Research and application of HBV RNA detection in monitoring the clinical cure of chronic hepatitis B patients [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2024, 12(02): 70-74.
[14]	Chunlin Liu, Chang Liu, Dongyan Zhao, Duanping Li, Jianmei Liu, Qiulin Luo. Evaluation of measurement uncertainty for HBV DNA and HCV RNA by using internal quality control and proficiency testing data [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2024, 12(02): 91-96.
[15]	Jiajia Li, Linghua Li, Shiyun Lv, Kai Feng, Linshan Liu, Haidan Zhong, Chan Yan, Cong Liu. Characteristics of genotype drug resistance and influencing factors of HIV/AIDS patients with virology failure in Guangzhou [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2024, 10(04): 207-212.

Please choose a citation manager

Content to export